AU3356000A - L-arginine based formulations for treating diseases and methods of using same - Google Patents

L-arginine based formulations for treating diseases and methods of using same

Info

Publication number
AU3356000A
AU3356000A AU33560/00A AU3356000A AU3356000A AU 3356000 A AU3356000 A AU 3356000A AU 33560/00 A AU33560/00 A AU 33560/00A AU 3356000 A AU3356000 A AU 3356000A AU 3356000 A AU3356000 A AU 3356000A
Authority
AU
Australia
Prior art keywords
methods
same
treating diseases
based formulations
arginine based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33560/00A
Inventor
Wayne H. Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitrosystems Inc
Original Assignee
Nitrosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitrosystems Inc filed Critical Nitrosystems Inc
Publication of AU3356000A publication Critical patent/AU3356000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU33560/00A 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same Abandoned AU3356000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11890399P 1999-02-05 1999-02-05
US60118903 1999-02-05
PCT/US2000/002798 WO2000045809A1 (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Publications (1)

Publication Number Publication Date
AU3356000A true AU3356000A (en) 2000-08-25

Family

ID=22381443

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33560/00A Abandoned AU3356000A (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Country Status (6)

Country Link
EP (1) EP1150669A4 (en)
JP (1) JP2002536325A (en)
AU (1) AU3356000A (en)
CA (1) CA2361575A1 (en)
MX (1) MXPA01007952A (en)
WO (1) WO2000045809A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
JP2002539257A (en) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド Increased drug bioavailability in the brain
JP5065570B2 (en) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 Vascular endothelial nitric oxide synthesis promoter
EP1663339B1 (en) * 2003-08-14 2013-07-31 Blue Medical Devices B.V. Endoluminal prosthesis comprising a therapeutic agent
EP1591118A1 (en) * 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
JP2012041296A (en) * 2010-08-19 2012-03-01 Medience Corp Vascular endothelial function improving agent, nitric oxide production promoter, and food and drink

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1994009786A1 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of hypertension
DE69432413T2 (en) * 1993-06-11 2004-05-13 The Board Of Trustees Of The Leland Stanford Junior University, Stanford TREATMENT OF DEGENERATIVE VESSEL DISEASES BY MODULATING THE ENDOGENIC NITROGEN PRODUCTION OR ACTIVITY
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
ES2224114T3 (en) * 1995-06-01 2005-03-01 N.V. Nutricia NUTRITIONAL CLINICAL COMPOSITION.
FR2774593B1 (en) * 1998-02-12 2000-05-05 Philippe Gorny OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds

Also Published As

Publication number Publication date
WO2000045809A1 (en) 2000-08-10
EP1150669A4 (en) 2005-06-22
JP2002536325A (en) 2002-10-29
CA2361575A1 (en) 2000-08-10
EP1150669A1 (en) 2001-11-07
MXPA01007952A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU7880700A (en) Compositions and methods of treatment for skin conditions using extracts of turmeric
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU9016898A (en) Methods and compositions for treatment of restenosis
AU3784999A (en) Methods for treatment of pain
AU7061200A (en) Compositions and method for treatment of acetaminophen intoxication
AU3356000A (en) L-arginine based formulations for treating diseases and methods of using same
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2420101A (en) Method and composition for the treatment of pain
AU3996799A (en) Alpha amino acid composition and method for the treatment of skin
AU2566201A (en) Compounds and methods for the treatment of pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase